Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Referral pattern to nephrologist and prognosis in diabetic kidney disease patients: Single center retrospective cohort study

  • Yukimasa Iwata,

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Visualization, Writing – original draft

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Terumasa Hayashi ,

    Roles Supervision

    t-hayashi@abelia.ocn.ne.jp

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Hiroki Okushima,

    Roles Data curation, Investigation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Ryuta Uwatoko,

    Roles Data curation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Taisuke Takatsuka,

    Roles Data curation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Daisuke Yoshimura,

    Roles Data curation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Tomohiro Kawamura,

    Roles Data curation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Rei Iio,

    Roles Data curation

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Yoshiyasu Ueda,

    Roles Supervision

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Tatsuya Shoji,

    Roles Supervision

    Affiliation Department of Kidney Disease and Hypertension, Osaka General Medical Center, Osaka, Japan

    ⨯
  • Yoshitaka Isaka

    Roles Supervision

    Affiliation Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan

    ⨯

Abstract

Background

Management of diabetic kidney disease (DKD) to prevent end-stage kidney disease (ESKD) has become a major challenge for health care professionals. This study aims to investigate the characteristics of patients with DKD when they are first referred to a nephrologist and the subsequent prognoses.

Methods

A total of 307 patients who were referred to our department from October 2010 to September 2014 at Osaka General Medical Center were analyzed. Independent risk factors associated with renal replacement therapy (RRT) and cardiovascular composite events (CVE) following their nephrology referral were later identified using Cox proportional hazards analysis.

Results

Of 307 patients, 26 (8.5%), 67 (21.8%), 134 (43.6%), and 80 (26.1%) patients were categorized as having chronic kidney disease (CKD) stages 3a, 3b, 4, and 5, respectively. The median estimated glomerular filtration rate (eGFR) and urinary protein levels were 22.3 mL/min/1.73 m2 and 2.83 g/gCr, respectively, at the time of the nephrology referral. During the follow-up period (median, 30 months), 121 patients required RRT, and more than half of the patients with CKD stages 5 and 4 reached ESKD within 60 months following their nephrology referral; 30% and <10% of the patients with CKD stages 3b and 3a, respectively, required RRT within 60 months following their nephrology referral.

Conclusion

Patients with DKD were referred to nephrologist at CKD stage 4. Although almost half of the patients with CKD stage 5 at the time of nephrology referral required RRT within one-and-a-half years after the referral, kidney function of patients who were referred to nephrologist at CKD stage 3 and 4 were well preserved.

Citation: Iwata Y, Hayashi T, Okushima H, Uwatoko R, Takatsuka T, Yoshimura D, et al. (2023) Referral pattern to nephrologist and prognosis in diabetic kidney disease patients: Single center retrospective cohort study. PLoS ONE 18(2): e0282163. https://doi.org/10.1371/journal.pone.0282163

Editor: Ferdinando Carlo Sasso, University of Campania Luigi Vanvitelli: Universita degli Studi della Campania Luigi Vanvitelli, ITALY

Received: July 4, 2022; Accepted: February 9, 2023; Published: February 24, 2023

Copyright: © 2023 Iwata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: Y.I received grant from Osaka Kidney Foundation (http://www.okf.ecnet.jp/). Grant number is OKF18-0001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD), accounting for 42.5% of the patients who started chronic dialysis in 2017, according to the registry of the Japanese Society for Dialysis Therapy [1]. On the other hand, most of diabetic patients do not develop ESKD, as they die before [2]. Therefore, management of DKD to prevent ESKD and improve overall survival has become a major challenge in public health and clinical medicine.

Although several guidelines recommend that patients with CKD should be referred to a nephrologist at the CKD stage G4 [3–6], a large proportion of patients with CKD are still referred to nephrologists in the late phase of CKD in real-world clinical settings [7, 8].

Moreover, previous reports have shown that early referral to nephrologists is crucial for improving the mortality and morbidity rates in patients on chronic dialysis [9–18]. Although multifactorial intervention significantly reduced the onset or progression of DKD in patients with type 2 diabetes mellitus [19], patients with advanced DKD, despite the worst renal and cardiovascular prognosis, are at high risk of being under-treated independently of the type of clinical setting (nephrology, diabetology and primary care) [20].

There are few reports concerning patient characteristics with DKD referred to nephrologists for the first time and the prognosis thereafter [21].

Thus, the first aim of our study was to investigate the characteristics of patients with DKD at their first nephrologist referral. The second aim of our study was to examine the renal outcomes, all-cause mortality, and cardiovascular events after nephrology referral as well as to identify the factors associated with outcomes.

Methods

Patients

This study was conducted in accordance with the guidelines of the Declaration of Helsinki. This study was approved by the ethical committees of Osaka General Medical Center (No. 29-S1001).

All data were fully anonymized before we accessed them and ethics committee waived the requirement for informed consent. We clearly informed the patients and their relatives that the opportunity to opt out was always available on our hospital website.

This was a single-center, retrospective cohort study. A total of 499 pre-dialysis patients with CKD and diabetes mellitus, who were referred to our department between October 2010 and September 2014, were enrolled; further, 92 patients were excluded from the analysis owing to nondiabetic renal disease confirmed by renal biopsy (n = 24) or hydronephrosis (n = 3), at the first nephrology referral. Those who did not have data on urinary protein creatinine ratio at their first nephrology visit (n = 24) and those with eGFR >60 mL/min/1.73 m2 (n = 41) were also excluded. Further, 131 patients were referred back to their primary physicians because they were found to be at a low risk for progression to ESKD, as confirmed by the examining nephrologists. Therefore, questionnaires on the outcomes were sent to the primary physicians; however, outcome information was available for only 31 patients. We excluded 100 patients owing to a lack of data on their outcomes. In total, 307 patients were retrospectively studied (Fig 1).

thumbnail
Download:
Fig 1. The flow chart of the study population.

https://doi.org/10.1371/journal.pone.0282163.g001

Data collection and definition

We collected the data of 307 patients from the electronic medical charts at Osaka General Medical Center, including demographics (sex and age), duration of diabetes mellitus, medications, comorbid conditions (history of cardiovascular disease, stroke, peripheral arterial disease, malignancy, and diabetic retinopathy), and clinical and laboratory variables (body mass index; blood pressure; heart rate; levels of serum creatinine, blood urea nitrogen, uric acid, hemoglobin, albumin, calcium, phosphate, intact parathyroid hormone, total cholesterol, low-density lipoprotein cholesterol, and glycated hemoglobin; and proteinuria). The glomerular filtration rate, at the nephrology referral, was estimated using the formula for Japanese people () [22]. The patients were divided into four groups according to their renal function and CKD category (G3a-G5).

Outcomes

The outcomes of interest in the present study were time to renal replacement therapy (RRT) and cardiovascular composite endpoints (CVE). CVE included all-cause death, coronary or peripheral revascularization, heart failure, or stroke. Patients were followed up after RRT initiation to evaluate the risk of CVE. RRT was defined as the requirement for maintenance dialysis or kidney transplantation. The index date was the day of the nephrology referral. The observation period lasted until December 2016. The median follow-up durations were 30 months (range, 11–43 months) and 35 months (range, 16.5–51 months) for RRT and CVE, respectively.

Statistical analyses

Continuous variables are presented as median [interquartile range (IQR]) and were compared using the Kruskal-Wallis test. Categorical variables are presented as numbers and percentages and were compared using Fisher’s exact test. The incidence rates of RRT and CVE were compared using Kaplan–Meier curves and log-rank tests. Cox proportional hazards model was used to estimate the risk of RRT and CVE using hazard ratios (HR) and 95% confidence intervals (CIs). A competing risk model was used to analyze the risk of two event types: RRT and death.

Furthermore, multivariate Cox proportional hazards model was used to identify independent risk factors associated with the outcomes. Independent variables associated with the outcome in univariate analysis (P<0.1) were included in the multivariate analysis. Statistical significance was set at P <0.05. All statistical analyses were performed using the EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [23].

Results

Baseline characteristics

At the nephrology referral, 26 (8.5%), 67 (21.8%), 134 (43.6%), and 80 (26.1%) patients were categorized as having CKD stages 3a, 3b, 4, and 5, respectively (Fig 1). Patient characteristics and baseline laboratory data for each group are listed in Table 1.

thumbnail
Download:
Table 1. Patient characteristics and laboratory data at nephrology referral by CKD stage.

https://doi.org/10.1371/journal.pone.0282163.t001

The median age was 69 years, and 70.7% of the patients were men. The median eGFR was 22.3 mL/min/1.73 m2 and urinary protein level was 2.83 g/gCr. The prevalence of heart failure significantly increased in CKD stages 4 and 5 compared with that in CKD stage 3. As CKD progressed, uric acid, phosphate, intact parathyroid hormone, and urinary protein levels increased, while hemoglobin, serum albumin, corrected calcium, and glycated hemoglobin levels decreased.

Patients without outcome information were older and had low blood urea nitrogen, uric acid, phosphate, and intact parathyroid hormone levels associated with high eGFR; of note, the urinary protein levels were lower and the eGFR was significantly higher in these patients than in the analyzed patients (S1 Table).

Renal outcome by CKD stage at nephrology referral

A total of 121 patients (39.4%) required RRT during the follow-up period. Kaplan–Meier analysis of renal outcomes showed a significant difference between the four groups (Fig 2). Moreover, almost half of the patients with CKD 5 reached ESKD within approximately 1 year after the nephrology referral.

thumbnail
Download:
Fig 2. Renal outcome by CKD stage.

https://doi.org/10.1371/journal.pone.0282163.g002

Renal function at the nephrology referral was significantly associated with renal outcomes in both univariate [hazards ratio (HR), 0.91; 95% confidence interval (CI): 0.89–0.93; P<0.001) and multivariate Cox analyses (HR, 0.91; 95% CI: 0.88–0.94; P<0.001). Furthermore, young age (HR, 0.96; 95% CI: 0.95–0.98; P<0.001), history of malignancy (HR, 2.77; 95% CI, 1.48–5.16; P = 0.001), higher systolic blood pressure (HR, 1.01; 95% CI, 1.00–1.02; P = 0.026), and high serum albumin level (HR, 0.49; 95% CI: 0.34–0.71; P<0.001) were independently associated with renal outcomes in the multivariate analysis (Table 2).

thumbnail
Download:
Table 2. Indicators of renal outcome.

https://doi.org/10.1371/journal.pone.0282163.t002

During the follow-up period, 35 patients died. Sensitivity analysis of the multivariate analysis showed that renal function at the nephrology referral was significantly associated with renal outcomes, using a competing risk model (HR, 0.91; 95% CI: 0.88–0.94; P<0.001). Furthermore, young age, history of malignancy, and low serum albumin levels were independently associated with renal outcomes in the multivariate analysis (S1 Fig and S2 Table).

Association between CKD stage at nephrology referral and CVE

CVE occurred in 113 patients during the follow-up period, including 35 deaths from any cause, 21 from coronary artery disease, 39 from heart failure, 9 from peripheral artery disease, and 9 from stroke. Kaplan–Meier analysis of the cumulative incidence rate of CVE did not reveal a significant difference among the four groups (Fig 3). Renal function at the nephrology referral was not significantly associated with CVE (log-rank test, P = 0.264). As per the results of the multivariate Cox analysis for CVE, the significant variable was history of cardiovascular disease (HR, 1.64; 95% CI: 1.10–2.44; P = 0.015) (Table 3).

thumbnail
Download:
Fig 3. Cardiovascular composite outcome by CKD stage.

https://doi.org/10.1371/journal.pone.0282163.g003

thumbnail
Download:
Table 3. Indicators of CVE.

https://doi.org/10.1371/journal.pone.0282163.t003

Discussion

Timely referral to a nephrologist and adequate care of patients with CKD are important aspects for improving clinical outcomes. The benefits of early referral to a nephrologist have been well-established in previous studies [9–18, 24]. Several guidelines recommend early nephrology referral, especially for certain patients whose renal function declined rapidly, such as those with DKD [5, 6].

Although many clinicians recognize the importance of timely nephrology referral in patients with CKD, a large proportion of CKD patients are still referred late in the real-world clinical settings [7, 8], and there are few reports on the characteristics of DKD patients at the nephrology referral and their outcomes. The present study showed that 70% of the patients with DKD were referred to a nephrologist at CKD stage 4 or 5.

Pinier et al. reported that the eGFR at nephrology referral declined to 42.2 mL/min/1.73 m2 in DKD patients, whose mean age was 70.3 years. In this study, 26.3% of the patients were referred to a nephrologist for reasons other than decreased renal function, albuminuria, and hypertension [25] indicating that renal function in these patients may be maintained.

Because the patients in our study were referred to our department mainly for declined renal function and albuminuria, the renal function of our patients had declined to 22.3 mL/min/1.73 m2 at the time of referral.

Although more than half of the patients with CKD stages 5 and 4 reached ESKD within 60 months after the nephrology referral, 30% and <10% of the patients, with CKD stages 3b and 3a, respectively required RRT within 60 months. The renal outcomes in our study were worse than those reported in previous studies, such as RENAAL and IDNT [26, 27]. The reason for this may be that patients with a low risk of progression to ESKD after examination by nephrologists were referred back to their primary physicians, and of the 131 patients, we could investigate only 31 patients’ outcomes.

Our results suggest that nephrology referral until CKD stage 3a is important for DKD patients, and these patients should be referred to a nephrologist until CKD stage 3b even if their renal function declines to less than eGFR 45 mL/min/1.73 m2.

In previous reports, the eGFR of patients with type 1 and 2 diabetes declined to 9.1 and 0.5–1.9 mL/min/1.73 m2/year, respectively [28, 29]. The renal function of our patients declined rapidly because they had higher levels of proteinuria than those reported in previous reports. It was also reported that diabetic retinopathy could predict subsequent cardiovascular events in patients with diabetes mellitus [30]; however, due to the retrospective nature of this study, we didn’t have enough data on diabetic retinopathy, so we could not investigate the association between diabetic retinopathy and CVE onset.

Renin-angiotensin system inhibitors have been found to reduce urinary protein levels and improve renal outcomes in patients with DKD [26, 27]. Nephrological care, including low-protein diet, appropriate blood pressure control, and use of renin-angiotensin system inhibitors, is useful for decreasing urinary protein excretion. Martínez-Ramírez et al. showed that nephrologists prescribed renin-angiotensin system inhibitors more frequently than family physicians, leading to increased renal function preservation in patients with diabetes mellitus [31].

In our study, urinary protein excretion was not independently associated with renal outcomes in the multivariate analysis but lower serum albumin associated with renal outcomes. We measured urinary protein excretion as spot urine protein-creatinine ratio and it is already known that spot urine albumin-creatinine ratio had day-to-day variability [32]. In addition, the number of RRT was relatively small. For above reasons we could not find the significant relation between renal outcomes and urinary protein excretion.

Renal function, albuminuria, and history of cardiovascular disease have been found to be associated with the incidence of cardiovascular disease in patients with CKD in previous reports [33–35].

In the present study, history of cardiovascular disease was associated with CVE in the multivariate analysis, but renal function and urinary protein excretion were not. One of the considerable reasons is that the number of CVE is small in the present study and it is reported that incidences of cardiovascular disease in CKD patients is lower in Japan compared to those in other countries [36].

We previously reported that more than 20 months of pre-dialysis nephrological care may be needed to improve the first-year mortality after dialysis initiation [18]. However, Fig 2 shows that more than 50% of the patients with CKD 5 and almost 20% with CKD 4 required RRT within 20 months of the nephrology referral. Previous reports have shown that in patients with DKD early nephrology referral not only preserves renal function but is also associated with better overall survival even if the patients need chronic dialysis treatment [25, 31].

Moreover, recently, new renoprotective agents have been developed for the treatment of DKD, such as sodium glucose cotransporter 2 (SGLT2) inhibitors, selonsertib, finerenone, and atrasentan [37–43]. However, the target patients in those clinical trials were restricted to those with eGFR of 20–25 mL/min/1.73 m2 or more. In other words, the impact of these agents on the advanced stages of DKD has not been revealed. Thus, early referral to nephrologists is necessary to slow the progression of DKD with the help of both renin-angiotensin system inhibitors and these new agents.

In addition to renoprotective effects, these new agents, such as SGLT2 inhibitors and finerenone, improve the cardiovascular outcomes [38, 42, 44, 45]. However, because these studies excluded patients with eGFR of 25–30 mL/min/1.73 m2 or less and furthermore, in the present study, SGLT2 inhibitors were not widely used, so it is not clear whether these agents will improve the cardiovascular outcomes in patients with advanced stages of DKD.

The present study had some limitations. First, this study was a single-center retrospective cohort study; however, the inclusion of a relatively large number of study patients, collection of data from electronic medical charts, and high-quality outcome survey improved our analyses.

Second, we did not investigate the treatment details after the nephrology referral, such as blood pressure, fluid and mineral levels, bone disorders, anemia, metabolic acidosis, glycemic control and medications.

Third, we did not investigate if the patients received primary care before the nephrology referral. Some patients who did not receive primary care visited the emergency room with advanced CKD at the last moment, requiring emergency dialysis.

Fourth, we did not consider the effects of dialysis initiation, including medication use and dialysis efficiency. The patients in the present study were similarly managed at various dialysis centers based on several clinical guidelines.

Fifth, our hospital is a tertiary hospital; therefore, the prevalence of patients with multiple and severe comorbidities, including cardiovascular disease and malignancy, was extremely high. This may have affected the results of this study.

Conclusion

Our results suggest that the eGFR in patients with DKD had declined to 22.3 mL/min/1.73 m2 at their nephrology referral and almost half of the patients with CKD stage 5 at the referral required RRT within one-and-a-half year after the referral, while kidney function in patients with CKD stages 3 and 4 was well preserved. Further studies are needed to identify the optimal timing for nephrology referral to improve the prognosis of patients with DKD.

Supporting information

S1 Fig. Renal outcome by CKD stage (competing risk model).

https://doi.org/10.1371/journal.pone.0282163.s001

(TIF)

S1 Table. Patient characteristics and laboratory data at nephrology referral compared to excluded patients.

https://doi.org/10.1371/journal.pone.0282163.s002

(TIF)

S2 Table. Indicators of renal outcome (competing risk model).

https://doi.org/10.1371/journal.pone.0282163.s003

(TIF)

References

  1. 1. Nitta K, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, et al. Annual dialysis data report 2017, JSDT renal data registry. Ren Replace Ther. 2019; 5: 53.
  2. 2. Sasso FC, Pafundi PC, Simeon V, Nicola LD, Chiodini P, Galiero R, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021; 20: 145. pmid:34271948
  3. 3. Japanese Society of Nephrology. Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol. 2014; 18: 346–423.
  4. 4. Watanabe Y, Yamagata K, Nishi S, Hirakata H, Hanafusa N, Saito C, et al. Japanese society for dialysis therapy clinical guideline for “hemodialysis initiation for maintenance hemodialysis.” Ther Apher Dial. 2015; 19; Suppl 1: 93–107.
  5. 5. Kidney Disease: Improving Global Outcome (KDIGO) CKD Work Group 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1–150.
  6. 6. Japanese Society of Nephrology. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019; 23: 1–15. pmid:30506489
  7. 7. Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A. Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. Am J Kidney Dis. 2007; 50: 733–42. pmid:17954286
  8. 8. Sud M, Tangri N, Levin A, Pintilie M, Levey AS, Naimark DM, et al. CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am J Kidney Dis. 2014; 63: 928–36. pmid:24485146
  9. 9. Hayashi T, Kimura T, Yasuda K, Sasaki K, Obi Y, Nagayama H, et al. Early nephrology referral 6 months before dialysis initiation can reduce early death but does not improve long-term cardiovascular outcome on dialysis. Circ J. 2016; 80: 1008–16. pmid:26876973
  10. 10. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant. 2001; 16: 2357–64. pmid:11733627
  11. 11. Kim DH, Kim M, Kim H, Kim TL, Kang SW, Yang CW, et al. Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in Korea. PLoS One. 2013; 8: e55323. pmid:23372849
  12. 12. Yamagata K, Nakai S, Masakane I, Hanafusa N, Iseki K, Tsubakihara Y, et al. Ideal timing and predialysis nephrology care duration for dialysis initiation: from analysis of Japanese dialysis initiation survey. Ther Apher Dial. 2012; 16: 54–62. pmid:22248196
  13. 13. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 2011; 124: 1073–80.e2. pmid:22017785
  14. 14. Stoves J, Bartlett CN, Newstead CG. Specialist follow up of patients before end stage renal failure and its relationship to survival on dialysis. Postgrad Med J 2001; 77: 586–8. pmid:11524518
  15. 15. Hasegawa T, Bragg-Gresham JL, Yamazaki S, Fukuhara S, Akizawa T, Kleophas W, et al. Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol. 2009; 4: 595–602. pmid:19261827
  16. 16. Kazmi WH, Obrador GT, Khan SS, Pereira BJG, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant. 2004; 19: 1808–14. pmid:15199194
  17. 17. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis. 2003; 41: 310–8. pmid:12552491
  18. 18. Iwata Y, Okushima H, Takatsuka T, Yoshimura D, Kawamura T, Iio R, et al. Duration of predialysis nephrological care and mortality after dialysis initiation. Clin Exp Nephrol. 2020; 24: 705–14. pmid:32281008
  19. 19. Ueki K, Sasako T, Okazaki Y, Miyake K, Nangaku M, Ohashi Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021; 99; 256–266. pmid:32891604
  20. 20. Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, et al. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens. 2006; 24; 1655–61. pmid:16877970
  21. 21. Ekart R, Ferjuc A, Furman B, Gerjevič Š, Bevc S, Hojs R. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease. Ther Apher Dial. 2013; 17: 363–7. pmid:23931872
  22. 22. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982–92. pmid:19339088
  23. 23. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–8. pmid:23208313
  24. 24. Obialo CI, Ofili EO, Quarshie A, Martin PC. Ultralate referral and presentation for renal replacement therapy: socioeconomic implications. Am J Kidney Dis. 2005; 46: 881–6. pmid:16253728
  25. 25. Pinier C, Gatault P, François M, Barbet C, Longuet H, Rabot N, et al. Renal function at the time of nephrology referral but not dialysis initiation as a risk for death in patients with diabetes mellitus. Clin Kidney J. 2018; 11: 762–8. pmid:30524709
  26. 26. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851–60. pmid:11565517
  27. 27. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861–9. pmid:11565518
  28. 28. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017; 91: 1300–11. pmid:28366227
  29. 29. Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013; 36: 2803–9. pmid:23620478
  30. 30. Sasso FC, Pafundi PC, Gelso A, Bono V, Costagliola C, Marfella R, et al. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. Nutr Metab Cardiovasc Dis. 2019; 29: 923–930. pmid:31377186
  31. 31. Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006; 47: 78–87. pmid:16377388
  32. 32. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013; 62: 1095–101. pmid:23958401
  33. 33. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–305. pmid:15385656
  34. 34. Hui X, Matsushita K, Sang Y, Ballew SH, Fülöp T, Coresh J. CKD and cardiovascular disease in the atherosclerosis risk in communities (ARIC) study: interactions with age, sex, and race. Am J Kidney Dis. 2013; 62: 691–702. pmid:23769137
  35. 35. Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018; 13: e0192895. pmid:29561894
  36. 36. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017; 91: 227–234. pmid:27884399
  37. 37. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–34. pmid:27299675
  38. 38. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295–306. pmid:30990260
  39. 39. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015; 314: 884–94. pmid:26325557
  40. 40. Chertow GM, Pergola PE, Chen F, Kirby BJ, Sundy JS, Patel UD, et al. Effects of selonsertib in patients with diabetic kidney disease. J Am Soc Nephrol. 2019; 30: 1980–90. pmid:31506292
  41. 41. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014; 25: 1083–93. pmid:24722445
  42. 42. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–46. pmid:32970396
  43. 43. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med. 2020; 383: 2219–29. pmid:33264825
  44. 44. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossuing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and Type 2 diabetes. Circulation. 2021; 143: 540–52. pmid:33198491
  45. 45. Nevola R, Alfano M, Pafundi PC, Brin C, Gragnano F, Calabrò P, et al. Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Rev Cardiovasc Med. 2022; 23; 106 pmid:35345273